Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Astrazeneca Plc (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
AstraZeneca's (AZN) Lynparza Gets Another Orphan Drug Status

AstraZeneca (AZN) and partner Merck's Lynparza receive Orphan Drug designation (ODD) by the FDA for the treatment of pancreatic cancer.

CELG : 83.83 (-0.53%)
AZN : 39.21 (+0.33%)
MRK : 71.70 (+0.67%)
LLY : 112.81 (+1.60%)
3 Large-Cap Pharma Stocks Performing Better Than Industry

We focus on three large-cap pharma stocks that are outperforming the industry on the back of their diverse portfolio.

AZN : 39.21 (+0.33%)
MRK : 71.70 (+0.67%)
LLY : 112.81 (+1.60%)
NVS : 85.47 (-0.29%)
SNY : 44.75 (+0.90%)
J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion

Johnson & Johnson's (JNJ) Xarelto gets FDA approval for reducing risk of major cardiovascular events in chronic coronary or peripheral artery disease patients.

BAYRY : 22.4900 (-1.45%)
AZN : 39.21 (+0.33%)
JNJ : 139.88 (+2.43%)
RHHBY : 29.8580 (-2.84%)
Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts

Merrimack (MACK) focuses on the development of its two early-stage pipeline candidates, MM-121 and MM-310. The candidates have been progressing well and are imperative to the company's growth.

CRSP : 39.14 (-1.16%)
AZN : 39.21 (+0.33%)
SNY : 44.75 (+0.90%)
MACK : 5.10 (+0.20%)
Immune Checkpoint Inhibitors Market is Anticipated to Cross US$ 25 Billion by 2022 Due to Increasing Prevalence of Cancer and Immune Diseases: Radiant Insights, Inc.

The global Immune Checkpoint Inhibitors Market is likely to witness a higher CAGR in the forecast period. Oncology is a wide field with various diagnoses and applications. Increase in cancer cases and...

AZN : 39.21 (+0.33%)
MRK : 71.70 (+0.67%)
NVS : 85.47 (-0.29%)
Top Research Reports for JPMorgan, American Express & FedEx

Top Research Reports for JPMorgan, American Express & FedEx

CVS : 74.64 (+1.25%)
AZN : 39.21 (+0.33%)
JPM : 110.52 (+1.75%)
AXP : 105.03 (+0.73%)
PEP : 108.54 (+1.07%)
FDX : 225.42 (-0.34%)
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

Sector ETF report for PPH

AZN : 39.21 (+0.33%)
PJP : 70.50 (-0.11%)
IHE : 162.87 (+0.33%)
PPH : 62.81 (-0.13%)
PFE : 44.77 (+1.91%)
BMY : 58.89 (+1.83%)
5 Reasons Why Investors Should Bet on Merck (MRK) Stock

Here are some reasons why investors may consider putting their money into Merck (MRK) stock.

AZN : 39.21 (+0.33%)
MRK : 71.70 (+0.67%)
INCY : 65.07 (+0.25%)
AMGN : 201.68 (-0.33%)
Pharma Stock Roundup: PFE to Get New CEO, LLY Presents Impressive Diabetes Data

Pfizer (PFE) CEO, Ian Read to be replaced by present chief operating officer. Pipeline updates from Lilly (LLY), Novartis (NVS), J&J (JNJ) and others.

AZN : 39.21 (+0.33%)
MRK : 71.70 (+0.67%)
JNJ : 139.88 (+2.43%)
LLY : 112.81 (+1.60%)
RHHBY : 29.8580 (-2.84%)
PFE : 44.77 (+1.91%)
Lilly's Novel Diabetes Candidate Shows Promise in Phase II

Lilly's (LLY) dual GIP and GLP-1 receptor agonist demonstrates impressive reduction in blood sugar levels as well as body weight in type II diabetes patients.

AZN : 39.21 (+0.33%)
NVO : 43.50 (+0.25%)
LLY : 112.81 (+1.60%)
RHHBY : 29.8580 (-2.84%)
Dow 30 Stock Roundup: Boeing Wins $9.2B Pilot Training Deal, Intel Keeps '18 View

The index advanced strongly this week before suffering a sharp decline on Thursday.

MSFT : 110.89 (-0.10%)
EQNR : 27.10 (-1.02%)
CVX : 116.83 (-0.58%)
AZN : 39.21 (+0.33%)
INTC : 46.04 (+0.22%)
PFE : 44.77 (+1.91%)
BA : 367.30 (-0.26%)
WMT : 96.34 (+0.55%)
Clovis' Rubraca Gets Breakthrough Therapy Status for mCRPC

Clovis' (CLVS) cancer drug, Rubraca, gets Breakthrough Therapy designation from the FDA for treating metastatic castration resistant prostate cancer with BRCA mutation.

AZN : 39.21 (+0.33%)
MRK : 71.70 (+0.67%)
CLVS : 30.44 (-0.29%)
TSRO : 44.59 (+2.74%)
QIAGEN's FDA Nod for Expanded EGFR Test Use Widens Suite

QIAGEN (QGEN) continues to expand test menu; latest FDA approval to boost portfolio.

AZN : 39.21 (+0.33%)
DSRLF : 92.9300 (-14.14%)
QGEN : 35.30 (+0.48%)
PFE : 44.77 (+1.91%)
Roche Gets FDA Approval for New Formulation of Asthma Drug

Roche (RHHBY) receives FDA approval for a dose prefilled syringe (PFS) formulation of its asthma drug, Xolair.

AZN : 39.21 (+0.33%)
NVS : 85.47 (-0.29%)
RHHBY : 29.8580 (-2.84%)
GSK : 39.78 (-0.05%)
Sanofi/Regeneron's Cemiplimab Wins FDA Nod for Skin Cancer

Sanofi (SNY)/Regeneron's (REGN) anti- PD-1 drug cemiplimab wins FDA approval for a type of skin cancer.

AZN : 39.21 (+0.33%)
MRK : 71.70 (+0.67%)
REGN : 399.59 (+0.27%)
SNY : 44.75 (+0.90%)
Pfizer's (PFE) Lung Cancer Drug Vizimpro Gets FDA Approval

The FDA approves Pfizer's (PFE) Vizimpro for first-line treatment of locally advanced or metastatic non-small cell lung cancer in patients with epidermal growth factor receptor activating mutations.

AZN : 39.21 (+0.33%)
MRK : 71.70 (+0.67%)
PFE : 44.77 (+1.91%)
BMY : 58.89 (+1.83%)
Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs

FDA grants approval to Lilly's (LLY) Emgality for migraine and Pfizer's (PFE) Vizimpro for an advanced lung cancer indication. Novartis (NVS) to cut more than 2,000 jobs in Switzerland and U.K

AZN : 39.21 (+0.33%)
AGN : 191.86 (+2.06%)
LLY : 112.81 (+1.60%)
NVS : 85.47 (-0.29%)
ABBV : 92.07 (+0.17%)
PFE : 44.77 (+1.91%)
GSK : 39.78 (-0.05%)
Report: Developing Opportunities within AstraZeneca, Manulife Financial, Infosys, Novartis AG, Black Hills, and Shell Midstream Partners -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AstraZeneca PLC (NYSE:AZN),...

AZN : 39.21 (+0.33%)
SHLX : 21.45 (-0.97%)
INFY : 9.85 (-3.62%)
NVS : 85.47 (-0.29%)
MFC : 15.79 (+2.00%)
BKH : 61.29 (+0.74%)
Allergan Eyes Vraylar Label Expansion, FDA Accepts sNDA

FDA accepts Allergan's (AGN) sNDA for label expansion of its schizophrenia drug, Vraylar (cariprazine) to include treatment of bipolar depression.

AZN : 39.21 (+0.33%)
JNJ : 139.88 (+2.43%)
AGN : 191.86 (+2.06%)
ALKS : 41.12 (-2.84%)
Company News For Sep 26, 2018

Companies in the news are: FDS, SONC, AZN and EVHC

FDS : 217.72 (+0.37%)
AZN : 39.21 (+0.33%)
SONC : 43.25 (-0.12%)
EVHC : 45.99 (+0.02%)

Van Meerten Stock Picks

Tesla According to Peter Lynch
Today's Barchart Chart of the Day will be the auto maker Tesla (TSLA).
TSLA -7.88
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

cmdty Insider - Ag Market Commentary

Today's Commentary

Corn futures are currently fractionally lower after seeing 3 cent losses in most nearby contracts on Turnaround Tuesday profit taking. A drier pattern this week should allow producers in the Corn Belt to make better harvest progress. Monday’s C...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar